Segall Bryant & Hamill’s Catalyst Pharmaceutical CPRX Stock Holding History

Segall Bryant & Hamill’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-138,585	Closed	-$3.43M	–	602
2026 Q1	$3.43M	Sell	138,585 -5,335	-4%	-$127K	0.05%	350
2025 Q4	$3.36M	Buy	143,920 +63,452	+79%	+$1.41M	0.05%	365
2025 Q3	$1.59M	Sell	80,468 -376	-0.5%	-$7.73K	0.02%	460
2025 Q2	$1.75M	Sell	80,844 -11,092	-12%	-$262K	0.02%	455
2025 Q1	$2.23M	Buy	91,936 +11,582	+14%	+$261K	0.03%	412
2024 Q4	$1.68M	Buy	80,354 +39,721	+98%	+$853K	0.02%	461
2024 Q3	$808K	Buy	+40,633	New	+$753K	0.01%	524

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Segall Bryant & Hamill's CPRX Position: Q2 2026 in Review

Segall Bryant & Hamill sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 138,585 shares — an estimated $3.43M sold.

Segall Bryant & Hamill first reported a position in CPRX in Q3 2024 and held it in 7 quarters. The position peaked at $3.43M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Segall Bryant & Hamill reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Segall Bryant & Hamill sold 138,585 Catalyst Pharmaceutical shares in Q2 2026, an estimated $3.43M.
Segall Bryant & Hamill first reported a position in Catalyst Pharmaceutical in Q3 2024 and held it in 7 quarters.
Segall Bryant & Hamill's Catalyst Pharmaceutical position peaked at $3.43M in Q1 2026.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.